REED JOHN C
Director; EVP, Innovative Medicine, R&D · 3 filings · Latest: Aug 15, 2026
JOHNSON & JOHNSON
MADRIGAL PHARMACEUTICALS, INC.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | May 1, 2026 | Option Exercise | $0.00 | 25,255 | — | 35,913 | |
JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | $243.00 | 53,931 | $13.1M | 10,658 | |
JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | Feb 17, 2026 | Option Exercise | $156.89 | 51,648 | $8.1M | 42,868 | |
JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | Feb 15, 2026 | Option Exercise | $0.00 | 3,196 | — | 13,469 | |
JNJ | REED JOHN C | — | Feb 17, 2026 | Proposed Sale | $243.00 | 53,931 | $13.1M | — | |
JNJ | REED JOHN C | — | Oct 17, 2025 | Proposed Sale | $192.71 | 21,721 | $4.2M | — | |
JNJ | REED JOHN C | — | Jul 17, 2025 | Proposed Sale | $163.55 | 19,137 | $3.1M | — |